The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-05-29

AUTHORS

Shuren Li, Markus Peck-Radosavljevic, Philipp Ubl, Wolfgang Wadsak, Markus Mitterhauser, Eva Rainer, Matthias Pinter, Hao Wang, Christian Nanoff, Klaus Kaczirek, Alexander Haug, Marcus Hacker

ABSTRACT

PURPOSE: This prospective study was to investigate the value of [11C]-acetate PET and [18F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab). METHODS: Twenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified by histopathology were treated with TACE and bevacizumab (n = 11) or placebo (n = 11). [11C]-acetate PET and [18F]-FDG PET were performed before and after TACE with bevacizumab or placebo. Comparisons between groups were performed with t-tests and Chi-squared tests, where appropriate. Overall survival (OS) was defined as the time from start of bevacizumab or placebo until the date of death/last follow-up, respectively. RESULTS: The patient-related sensitivity of [11C]-acetate PET, [18F]-FDG PET, and combined [11C]-acetate and [18F]-FDG PET was 68%, 45%, and 73%, respectively. There was a significantly higher rate of conversion from [11C]-acetate positive lesions to negative lesions in patients treated with TACE and bevacizumab as compared with that in patients with TACE and placebo (p < 0.05). In patients with negative acetate PET, the mean OS in patients treated with TACE and bevacizumab was 259 ± 118 days and was markedly shorter as compared with that (668 ± 217 days) in patients treated with TACE and placebo (p < 0.05). In patients treated with TACE and placebo, there was significant difference in mean OS in patients with positive FDG PET as compared with that in patients with negative FDG PET (p < 0.05). The HCC lesions had different tracer avidities showing the heterogeneity of HCC. CONCLUSIONS: Our study suggests that combining [18F]-FDG with [11C]-acetate PET could be useful for the management of HCC patients and might also provide relevant prognostic and molecular heterogeneity information. More... »

PAGES

1732-1741

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-017-3724-2

DOI

http://dx.doi.org/10.1007/s00259-017-3724-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1085707524

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28555333


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acetates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arteries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bevacizumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carbon", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Hepatocellular", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemoembolization, Therapeutic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Li", 
        "givenName": "Shuren", 
        "id": "sg:person.0771074626.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771074626.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peck-Radosavljevic", 
        "givenName": "Markus", 
        "id": "sg:person.01046032607.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046032607.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ubl", 
        "givenName": "Philipp", 
        "id": "sg:person.01176542460.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176542460.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wadsak", 
        "givenName": "Wolfgang", 
        "id": "sg:person.0675305224.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675305224.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mitterhauser", 
        "givenName": "Markus", 
        "id": "sg:person.01356437224.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356437224.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rainer", 
        "givenName": "Eva", 
        "id": "sg:person.010420703627.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010420703627.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinter", 
        "givenName": "Matthias", 
        "id": "sg:person.01025230723.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025230723.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.413106.1", 
          "name": [
            "Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Hao", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute of Pharmacology, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Institute of Pharmacology, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nanoff", 
        "givenName": "Christian", 
        "id": "sg:person.01036057403.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036057403.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Surgery, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaczirek", 
        "givenName": "Klaus", 
        "id": "sg:person.01163404744.70", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163404744.70"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haug", 
        "givenName": "Alexander", 
        "id": "sg:person.01303705311.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303705311.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria", 
          "id": "http://www.grid.ac/institutes/grid.22937.3d", 
          "name": [
            "Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hacker", 
        "givenName": "Marcus", 
        "id": "sg:person.0721223765.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721223765.92"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00508-011-0056-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011637112", 
          "https://doi.org/10.1007/s00508-011-0056-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-002-0787-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024804125", 
          "https://doi.org/10.1007/s00259-002-0787-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/aso.2003.10.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024852350", 
          "https://doi.org/10.1245/aso.2003.10.002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00259-016-3449-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042648167", 
          "https://doi.org/10.1007/s00259-016-3449-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605580", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014737885", 
          "https://doi.org/10.1038/sj.bjc.6605580"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm988", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003700365", 
          "https://doi.org/10.1038/nm988"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-05-29", 
    "datePublishedReg": "2017-05-29", 
    "description": "PURPOSE: This prospective study was to investigate the value of [11C]-acetate PET and [18F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab).\nMETHODS: Twenty-two patients (three women, 19 men; 62\u00a0\u00b1\u00a08\u00a0years) with HCC verified by histopathology were treated with TACE and bevacizumab (n\u00a0=\u00a011) or placebo (n\u00a0=\u00a011). [11C]-acetate PET and [18F]-FDG PET were performed before and after TACE with bevacizumab or placebo. Comparisons between groups were performed with t-tests and Chi-squared tests, where appropriate. Overall survival (OS) was defined as the time from start of bevacizumab or placebo until the date of death/last follow-up, respectively.\nRESULTS: The patient-related sensitivity of [11C]-acetate PET, [18F]-FDG PET, and combined [11C]-acetate and [18F]-FDG PET was 68%, 45%, and 73%, respectively. There was a significantly higher rate of conversion from [11C]-acetate positive lesions to negative lesions in patients treated with TACE and bevacizumab as compared with that in patients with TACE and placebo (p\u00a0<\u00a00.05). In patients with negative acetate PET, the mean OS in patients treated with TACE and bevacizumab was 259\u00a0\u00b1\u00a0118\u00a0days and was markedly shorter as compared with that (668\u00a0\u00b1\u00a0217\u00a0days) in patients treated with TACE and placebo (p\u00a0<\u00a00.05). In patients treated with TACE and placebo, there was significant difference in mean OS in patients with positive FDG PET as compared with that in patients with negative FDG PET (p\u00a0<\u00a00.05). The HCC lesions had different tracer avidities showing the heterogeneity of HCC.\nCONCLUSIONS: Our study suggests that combining [18F]-FDG with [11C]-acetate PET could be useful for the management of HCC patients and might also provide relevant prognostic and molecular heterogeneity information.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00259-017-3724-2", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "10", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "mean overall survival", 
      "transarterial chemoembolization", 
      "FDG-PET", 
      "overall survival", 
      "acetate PET", 
      "hepatocellular carcinoma", 
      "vascular endothelial growth factor antibody", 
      "heterogeneity of HCC", 
      "start of bevacizumab", 
      "negative FDG-PET", 
      "growth factor antibody", 
      "positive FDG-PET", 
      "chi-squared test", 
      "prospective study", 
      "factor antibody", 
      "HCC patients", 
      "positive lesions", 
      "HCC lesions", 
      "placebo", 
      "bevacizumab", 
      "tracer avidity", 
      "negative lesions", 
      "patients", 
      "death/", 
      "lesions", 
      "chemoembolization", 
      "significant differences", 
      "carcinoma", 
      "high rate", 
      "treatment", 
      "PET", 
      "histopathology", 
      "FDG", 
      "antibodies", 
      "avidity", 
      "survival", 
      "study", 
      "days", 
      "test", 
      "group", 
      "management", 
      "differences", 
      "evaluation", 
      "start", 
      "sensitivity", 
      "rate", 
      "date", 
      "heterogeneity", 
      "acetate", 
      "heterogeneity information", 
      "values", 
      "time", 
      "comparison", 
      "information", 
      "conversion", 
      "endothelial growth factor (VEGF) antibody", 
      "patient-related sensitivity", 
      "acetate positive lesions", 
      "negative acetate PET", 
      "different tracer avidities", 
      "molecular heterogeneity information"
    ], 
    "name": "The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab", 
    "pagination": "1732-1741", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1085707524"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-017-3724-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28555333"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-017-3724-2", 
      "https://app.dimensions.ai/details/publication/pub.1085707524"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:40", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_752.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00259-017-3724-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-017-3724-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-017-3724-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-017-3724-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-017-3724-2'


 

This table displays all metadata directly associated to this object as RDF triples.

296 TRIPLES      22 PREDICATES      109 URIs      95 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-017-3724-2 schema:about N0c909de67fe24a1ba8687551b38cafb4
2 N2badf773cd7f45c197c0d8481a63ee7e
3 N2faae460216d467e93048139bec13a94
4 N421b1a2533b14ba5b139fd341181b749
5 N56661b68d8624122aa5fcf7fc871421d
6 N64b8c01011524121a558ebfd0dd8236e
7 N68d797878ed644558911c8bd80aea6cd
8 N7f039759ee6542b29e34d1607fcd4135
9 N818e35a29b6144608b83bad48ddfa7c6
10 N93c9ffab98104842aa22b7900b335bda
11 N9a82f27d6e4c40638809eb02026211f9
12 Na1fe10aca10d4b4e9497f80f864cabf0
13 Nbd1b821ea9ac41c19799e7328e36c677
14 Nc2d0c0f1ade04d3387247724f4074b7c
15 Ndeb4353ea312489cb9a7c9eede28f106
16 Nf588f021f4634ee6b8c88f040829038f
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N26075ac8d44e44bc86f5a40b7efbb705
20 schema:citation sg:pub.10.1007/s00259-002-0787-4
21 sg:pub.10.1007/s00259-016-3449-7
22 sg:pub.10.1007/s00508-011-0056-2
23 sg:pub.10.1038/nm988
24 sg:pub.10.1038/sj.bjc.6605580
25 sg:pub.10.1245/aso.2003.10.002
26 schema:datePublished 2017-05-29
27 schema:datePublishedReg 2017-05-29
28 schema:description PURPOSE: This prospective study was to investigate the value of [<sup>11</sup>C]-acetate PET and [<sup>18</sup>F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab). METHODS: Twenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified by histopathology were treated with TACE and bevacizumab (n = 11) or placebo (n = 11). [<sup>11</sup>C]-acetate PET and [<sup>18</sup>F]-FDG PET were performed before and after TACE with bevacizumab or placebo. Comparisons between groups were performed with t-tests and Chi-squared tests, where appropriate. Overall survival (OS) was defined as the time from start of bevacizumab or placebo until the date of death/last follow-up, respectively. RESULTS: The patient-related sensitivity of [<sup>11</sup>C]-acetate PET, [<sup>18</sup>F]-FDG PET, and combined [<sup>11</sup>C]-acetate and [<sup>18</sup>F]-FDG PET was 68%, 45%, and 73%, respectively. There was a significantly higher rate of conversion from [<sup>11</sup>C]-acetate positive lesions to negative lesions in patients treated with TACE and bevacizumab as compared with that in patients with TACE and placebo (p &lt; 0.05). In patients with negative acetate PET, the mean OS in patients treated with TACE and bevacizumab was 259 ± 118 days and was markedly shorter as compared with that (668 ± 217 days) in patients treated with TACE and placebo (p &lt; 0.05). In patients treated with TACE and placebo, there was significant difference in mean OS in patients with positive FDG PET as compared with that in patients with negative FDG PET (p &lt; 0.05). The HCC lesions had different tracer avidities showing the heterogeneity of HCC. CONCLUSIONS: Our study suggests that combining [<sup>18</sup>F]-FDG with [<sup>11</sup>C]-acetate PET could be useful for the management of HCC patients and might also provide relevant prognostic and molecular heterogeneity information.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N0ffeb3abe8544a21bbcf2108c3ad16d7
33 Nf6695e8d8ba24886af4bd3a15161e8c5
34 sg:journal.1297401
35 schema:keywords FDG
36 FDG-PET
37 HCC lesions
38 HCC patients
39 PET
40 acetate
41 acetate PET
42 acetate positive lesions
43 antibodies
44 avidity
45 bevacizumab
46 carcinoma
47 chemoembolization
48 chi-squared test
49 comparison
50 conversion
51 date
52 days
53 death/
54 differences
55 different tracer avidities
56 endothelial growth factor (VEGF) antibody
57 evaluation
58 factor antibody
59 group
60 growth factor antibody
61 hepatocellular carcinoma
62 heterogeneity
63 heterogeneity information
64 heterogeneity of HCC
65 high rate
66 histopathology
67 information
68 lesions
69 management
70 mean overall survival
71 molecular heterogeneity information
72 negative FDG-PET
73 negative acetate PET
74 negative lesions
75 overall survival
76 patient-related sensitivity
77 patients
78 placebo
79 positive FDG-PET
80 positive lesions
81 prospective study
82 rate
83 sensitivity
84 significant differences
85 start
86 start of bevacizumab
87 study
88 survival
89 test
90 time
91 tracer avidity
92 transarterial chemoembolization
93 treatment
94 values
95 vascular endothelial growth factor antibody
96 schema:name The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab
97 schema:pagination 1732-1741
98 schema:productId N5e9af8b909e74b0482b5f5c473ad663c
99 Nc1912b39e8bb407999b47ab33657bea1
100 Ne8b8d14c149749169e7edfb2015034a6
101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085707524
102 https://doi.org/10.1007/s00259-017-3724-2
103 schema:sdDatePublished 2021-12-01T19:40
104 schema:sdLicense https://scigraph.springernature.com/explorer/license/
105 schema:sdPublisher N1c05ed3f46164d21ac89fdb6de8d7d6d
106 schema:url https://doi.org/10.1007/s00259-017-3724-2
107 sgo:license sg:explorer/license/
108 sgo:sdDataset articles
109 rdf:type schema:ScholarlyArticle
110 N0c909de67fe24a1ba8687551b38cafb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Male
112 rdf:type schema:DefinedTerm
113 N0ffeb3abe8544a21bbcf2108c3ad16d7 schema:volumeNumber 44
114 rdf:type schema:PublicationVolume
115 N1c05ed3f46164d21ac89fdb6de8d7d6d schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N26075ac8d44e44bc86f5a40b7efbb705 rdf:first sg:person.0771074626.92
118 rdf:rest N2d36fe79a09e4107be424ad138005e32
119 N2badf773cd7f45c197c0d8481a63ee7e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Arteries
121 rdf:type schema:DefinedTerm
122 N2d36fe79a09e4107be424ad138005e32 rdf:first sg:person.01046032607.37
123 rdf:rest N3ab79f6ea5674dfb95f38a94dfb7ed75
124 N2faae460216d467e93048139bec13a94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Chemoembolization, Therapeutic
126 rdf:type schema:DefinedTerm
127 N3499c2768cc540949f6681ac947be9c6 rdf:first sg:person.010420703627.71
128 rdf:rest N7f94011173f2463498e8d717f048c5e9
129 N3ab79f6ea5674dfb95f38a94dfb7ed75 rdf:first sg:person.01176542460.88
130 rdf:rest N7ef65eda375a483ca79e4cd873b362e8
131 N3ddbd691485a4256ae2d4432d8e1aceb schema:affiliation grid-institutes:grid.413106.1
132 schema:familyName Wang
133 schema:givenName Hao
134 rdf:type schema:Person
135 N421b1a2533b14ba5b139fd341181b749 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Humans
137 rdf:type schema:DefinedTerm
138 N534b17a4c440453b90bb30ae08c351e4 rdf:first sg:person.01163404744.70
139 rdf:rest Nd52b7b83ed9f4285b7fe3362dbec89ab
140 N56661b68d8624122aa5fcf7fc871421d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Aged
142 rdf:type schema:DefinedTerm
143 N5e9af8b909e74b0482b5f5c473ad663c schema:name dimensions_id
144 schema:value pub.1085707524
145 rdf:type schema:PropertyValue
146 N64b8c01011524121a558ebfd0dd8236e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Treatment Outcome
148 rdf:type schema:DefinedTerm
149 N68d797878ed644558911c8bd80aea6cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Carbon
151 rdf:type schema:DefinedTerm
152 N7ef65eda375a483ca79e4cd873b362e8 rdf:first sg:person.0675305224.33
153 rdf:rest Ndc2cee1a6c3c4f83a15e00e33bd4fd7e
154 N7f039759ee6542b29e34d1607fcd4135 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Liver Neoplasms
156 rdf:type schema:DefinedTerm
157 N7f94011173f2463498e8d717f048c5e9 rdf:first sg:person.01025230723.21
158 rdf:rest Ne83f206e07af46fcbdeb612a492aca55
159 N818e35a29b6144608b83bad48ddfa7c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Positron-Emission Tomography
161 rdf:type schema:DefinedTerm
162 N84e699404b7043fbb9021923e367596f rdf:first sg:person.0721223765.92
163 rdf:rest rdf:nil
164 N93c9ffab98104842aa22b7900b335bda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Carcinoma, Hepatocellular
166 rdf:type schema:DefinedTerm
167 N9a82f27d6e4c40638809eb02026211f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Survival Analysis
169 rdf:type schema:DefinedTerm
170 Na1fe10aca10d4b4e9497f80f864cabf0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Fluorodeoxyglucose F18
172 rdf:type schema:DefinedTerm
173 Na2e7b1d408234ebe9bf1d27bcd39cd54 rdf:first sg:person.01036057403.99
174 rdf:rest N534b17a4c440453b90bb30ae08c351e4
175 Nbd1b821ea9ac41c19799e7328e36c677 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Bevacizumab
177 rdf:type schema:DefinedTerm
178 Nc1912b39e8bb407999b47ab33657bea1 schema:name pubmed_id
179 schema:value 28555333
180 rdf:type schema:PropertyValue
181 Nc2d0c0f1ade04d3387247724f4074b7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Acetates
183 rdf:type schema:DefinedTerm
184 Nd52b7b83ed9f4285b7fe3362dbec89ab rdf:first sg:person.01303705311.52
185 rdf:rest N84e699404b7043fbb9021923e367596f
186 Ndc2cee1a6c3c4f83a15e00e33bd4fd7e rdf:first sg:person.01356437224.68
187 rdf:rest N3499c2768cc540949f6681ac947be9c6
188 Ndeb4353ea312489cb9a7c9eede28f106 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Female
190 rdf:type schema:DefinedTerm
191 Ne83f206e07af46fcbdeb612a492aca55 rdf:first N3ddbd691485a4256ae2d4432d8e1aceb
192 rdf:rest Na2e7b1d408234ebe9bf1d27bcd39cd54
193 Ne8b8d14c149749169e7edfb2015034a6 schema:name doi
194 schema:value 10.1007/s00259-017-3724-2
195 rdf:type schema:PropertyValue
196 Nf588f021f4634ee6b8c88f040829038f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Middle Aged
198 rdf:type schema:DefinedTerm
199 Nf6695e8d8ba24886af4bd3a15161e8c5 schema:issueNumber 10
200 rdf:type schema:PublicationIssue
201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
202 schema:name Medical and Health Sciences
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
205 schema:name Oncology and Carcinogenesis
206 rdf:type schema:DefinedTerm
207 sg:journal.1297401 schema:issn 1619-7070
208 1619-7089
209 schema:name European Journal of Nuclear Medicine and Molecular Imaging
210 schema:publisher Springer Nature
211 rdf:type schema:Periodical
212 sg:person.01025230723.21 schema:affiliation grid-institutes:grid.22937.3d
213 schema:familyName Pinter
214 schema:givenName Matthias
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025230723.21
216 rdf:type schema:Person
217 sg:person.01036057403.99 schema:affiliation grid-institutes:grid.22937.3d
218 schema:familyName Nanoff
219 schema:givenName Christian
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036057403.99
221 rdf:type schema:Person
222 sg:person.010420703627.71 schema:affiliation grid-institutes:grid.22937.3d
223 schema:familyName Rainer
224 schema:givenName Eva
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010420703627.71
226 rdf:type schema:Person
227 sg:person.01046032607.37 schema:affiliation grid-institutes:grid.22937.3d
228 schema:familyName Peck-Radosavljevic
229 schema:givenName Markus
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046032607.37
231 rdf:type schema:Person
232 sg:person.01163404744.70 schema:affiliation grid-institutes:grid.22937.3d
233 schema:familyName Kaczirek
234 schema:givenName Klaus
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01163404744.70
236 rdf:type schema:Person
237 sg:person.01176542460.88 schema:affiliation grid-institutes:grid.22937.3d
238 schema:familyName Ubl
239 schema:givenName Philipp
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176542460.88
241 rdf:type schema:Person
242 sg:person.01303705311.52 schema:affiliation grid-institutes:grid.22937.3d
243 schema:familyName Haug
244 schema:givenName Alexander
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01303705311.52
246 rdf:type schema:Person
247 sg:person.01356437224.68 schema:affiliation grid-institutes:grid.22937.3d
248 schema:familyName Mitterhauser
249 schema:givenName Markus
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01356437224.68
251 rdf:type schema:Person
252 sg:person.0675305224.33 schema:affiliation grid-institutes:grid.22937.3d
253 schema:familyName Wadsak
254 schema:givenName Wolfgang
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675305224.33
256 rdf:type schema:Person
257 sg:person.0721223765.92 schema:affiliation grid-institutes:grid.22937.3d
258 schema:familyName Hacker
259 schema:givenName Marcus
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0721223765.92
261 rdf:type schema:Person
262 sg:person.0771074626.92 schema:affiliation grid-institutes:grid.22937.3d
263 schema:familyName Li
264 schema:givenName Shuren
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0771074626.92
266 rdf:type schema:Person
267 sg:pub.10.1007/s00259-002-0787-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024804125
268 https://doi.org/10.1007/s00259-002-0787-4
269 rdf:type schema:CreativeWork
270 sg:pub.10.1007/s00259-016-3449-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042648167
271 https://doi.org/10.1007/s00259-016-3449-7
272 rdf:type schema:CreativeWork
273 sg:pub.10.1007/s00508-011-0056-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011637112
274 https://doi.org/10.1007/s00508-011-0056-2
275 rdf:type schema:CreativeWork
276 sg:pub.10.1038/nm988 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003700365
277 https://doi.org/10.1038/nm988
278 rdf:type schema:CreativeWork
279 sg:pub.10.1038/sj.bjc.6605580 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014737885
280 https://doi.org/10.1038/sj.bjc.6605580
281 rdf:type schema:CreativeWork
282 sg:pub.10.1245/aso.2003.10.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024852350
283 https://doi.org/10.1245/aso.2003.10.002
284 rdf:type schema:CreativeWork
285 grid-institutes:grid.22937.3d schema:alternateName Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
286 Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
287 Department of Surgery, Medical University of Vienna, Vienna, Austria
288 Institute of Pharmacology, Medical University of Vienna, Vienna, Austria
289 schema:name Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
290 Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
291 Department of Surgery, Medical University of Vienna, Vienna, Austria
292 Institute of Pharmacology, Medical University of Vienna, Vienna, Austria
293 rdf:type schema:Organization
294 grid-institutes:grid.413106.1 schema:alternateName Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
295 schema:name Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China
296 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...